A novel SARS-CoV-2 Beta RBD DNA vaccine directly targeted to antigen-presenting cells induces strong humoral and T cell responses

Throughout the COVID-19 pandemic, several variants of concern (VoC) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have evolved, affecting the efficacy of the approved COVID-19 vaccines. To address the need for vaccines that induce strong and persistent cross-reactive neutralizi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuczkowska, Katarzyna, Bjerkan, Louise, Stubsrud, Elisabeth, Husbyn, Hannah Cuthbertson, Chellappa, Stalin, Hauge, Anette, Skarshaug, Renate, Torgersen, Maria Lyngaas, Heim, Joel Benjamin, Jørgensen, Marthe Jøntvedt, Wold, Christian Winther, Schleimann, Mariane Høgsbjerg, Tolstrup, Martin, Granum, Stine, Fredriksen, Agnete Brunsvik, Pedersen, Mikkel Wandahl, Norheim, Gunnstein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622562/
https://www.ncbi.nlm.nih.gov/pubmed/37919366
http://dx.doi.org/10.1038/s41598-023-46223-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622562/
https://www.ncbi.nlm.nih.gov/pubmed/37919366
http://dx.doi.org/10.1038/s41598-023-46223-8

Ejemplares similares